Background
most common reasons for trial noncompletion. Among completed trials, 306 (66.5%) remained unpublished at 2 years and 142 (31.5%) at 4 years. In multivariable analyses, industry-funded trials were less likely to be discontinued than trials funded by healthcare centers (odds ratio [OR] 2.42; 95% confidence interval [CI] 1.34-4.39, P = 0.003). We found no significant association between funding source and time to publication. A total of 18,148 patients were enrolled in trials that were discontinued or unpublished 4 years after completion. A potential limitation of our study is that certain interventional trials for rare diseases may not have been registered in ClinicalTrials.gov, in particular Phase 0 and Phase I trials, which are not required to be registered.
Conclusions
In this study, over half of clinical trials initiated for rare diseases were either discontinued or not published 4 years after completion, resulting in large numbers of patients with rare diseases exposed to interventions that did not lead to informative findings. Concerted efforts are needed to ensure that participation of patients in rare disease trials advances scientific knowledge and treatments for rare diseases.
Author summary
Why was this study done?
• Rare diseases are a group of 7,000 conditions affecting approximately 60 million people in the US and Europe.
• Many rare diseases begin in childhood and are chronic conditions but lack therapeutic options because of the challenges of conducting trials in these populations.
• Clinical trial activities for rare diseases, including rates of trial completion and publication, have not been well defined.
What did the researchers do and find?
• We analyzed rare disease trials registered in a clinical trial registry from 2010 to 2012 and determined the frequencies of trial noncompletion and nonpublication through 2018.
• Among 659 randomized controlled trials, 199 (30.2%) were discontinued, most often because of difficulties with patient accrual.
• There were 306 (66.5%) trials that were not published 2 years after completion and 142 (31.5%) that remained unpublished 4 years after trial completion.
What do these findings mean?
• In our study, over half of randomized controlled trials studying rare diseases were not completed or were left unpublished 4 years after trial completion, highlighting considerable inefficiencies in research activities for these conditions.
Introduction
Rare diseases individually occur in fewer than 1 in 2,000 people but collectively affect almost 6% of people at some point during their lives [1] . There are approximately 7,000 rare diseases and 60 million people in the US and Europe who suffer from these conditions [1, 2] . Many rare diseases are chronic and life threatening. Since the majority are genetic in origin, three-quarters of rare diseases also affect children [3] . Examples of rare diseases include cystic fibrosis, Huntington disease, and Duchenne muscular dystrophy, as well as acquired conditions such as mesothelioma and botulism.
Because of a number of regulatory and financial incentives promoting drug development for rare diseases, there has been a substantial increase in available therapies for rare conditions over the past 30 years [4] . However, less than 10% of rare diseases have an available therapy, and as few as 22% of these conditions have been studied in drug trials [5, 6] . Challenges in performing rare disease trials include small and geographically dispersed patient populations, inaccurate diagnostic and effect measurements related to clinical heterogeneity, lack of validated clinical endpoints, and limited disease expertise in the medical community [7, 8] . Previous studies examining rare disease trials have shown that, compared to trials for nonrare diseases, rare disease trials tend to enroll fewer participants, use single-arm or nonrandomized designs, and measure surrogate endpoints as opposed to overall survival [9] .
Given the critical need for therapeutic development for rare diseases and the small patient populations available to generate robust clinical evidence, it is essential that clinical trials initiated for these conditions are completed and trial results disseminated in a timely fashion. To elucidate the epidemiology of randomized clinical trials studying rare diseases, our objective was to determine the frequency of noncompletion and nonpublication of rare disease trials and identify factors associated with these outcomes.
Methods

Data source
We conducted a cross-sectional analysis of randomized clinical trials focusing on rare diseases registered in ClinicalTrials.gov. The ClinicalTrials.gov query and data download were performed on a single day (March 3, 2017) to account for ongoing updates to database records. The Institutional Review Board at Boston Children's Hospital exempted this study from review because it did not represent human participant research. We followed a prospective protocol for data extraction, classification, and analysis (S1 Text).
We reviewed randomized clinical trials that were registered between January 1, 2010, and December 31, 2012, and completed or discontinued by December 31, 2014 . This timeframe was chosen to allow sufficient time for follow-up to trial publication. Discontinued trials were defined as those with a status of "terminated," "withdrawn," or "suspended" [10, 11] . We excluded trials registered more than 60 days after the start date to avoid bias related to decisions made after initial trial findings become available [10, 12] . Rare disease trials were identified using the ClinicalTrials.gov study topic of "Rare Diseases." Each trial entry was then manually reviewed by two of the authors (NP and CAR) to confirm the trial focused on a rare disease listed in the Genetic and Rare Disease (GARD) Information Center database, a resource compiled by the National Institutes of Health's National Center for Advancing Translational Sciences and the National Human Genome Research Institute [13] . Rare diseases were grouped according to categories provided by GARD [14] . If trials listed multiple conditions, more than half of the conditions needed to meet our definition of a rare disease in order for the trial to be included. Infectious disease trials were excluded because these diseases are often rare in developed nations but represent a large disease burden globally and therefore face different considerations around trial conduct compared to trials for noninfectious rare diseases.
Definitions and data characterization
We used the Glossary of Common Site Terms and ClinicalTrials.gov Protocol Data Element Definitions to define variables [10] . Primary funders were defined as the organization listed as the sponsor of a study. In cases when more than one sponsor was listed, the lead sponsor was designated as the primary funding source [15] . Funding sources in ClinicalTrials.gov are classified as industry, US government (National Institutes of Health and other US federal agencies), or "other," which includes foundations and research alliances. We created new funding variables for academic institutions and healthcare centers by reviewing all funders listed as "other." In addition, we added non-US government funding sources to US government to create our final funding sources of industry, academic institutions, healthcare centers, government, and other. We defined pediatric trials as those that exclusively studied children 0-17 years of age or those that also included adults but in which the midpoint of the age eligibility range was <18 years [16] . Based on trial locations listed in ClinicalTrials.gov, we classified trials as conducted entirely in the US, entirely outside of the US, or in both the US and other countries. We defined time to publication as the interval between the "primary completion date" and the date the publication appeared in print or as an electronic article, whichever occurred first. In cases when the primary completion date was missing (n = 31), we used the listed "completion date."
Reasons for trial noncompletion were determined based on data provided in ClinicalTrials. gov records. If the reason for noncompletion was not listed or unclear, we contacted study investigators and sponsors to obtain additional information. Reasons for noncompletion included insufficient patient accrual, informative termination (e.g., safety or toxicity concerns or interim study results indicating benefit or futility), company/business decisions, funding issues, conduct problems (e.g., insufficient study drug or technical problems with trial rollout), regulatory issues (e.g., difficulty obtaining approval from institutional review boards or other regulatory bodies), principal investigator departure, or none reported.
Publication search
We reviewed all trial entries in ClinicalTrials.gov to search for publications added via the national clinical trial (NCT) identifier number. For trials without a listed published article in the trial entry, Medline was searched via PubMed independently by two investigators (NP and CAR) using NCT number, trial title, author names, disease studied, intervention, study dates, and features of the study design. The search protocol was repeated in both EMBASE and GoogleScholar if no publication was identified in Medline. For industry-sponsored trials, we also searched company websites for publication information, as needed.
If a trial could not be linked to a published article, we contacted study investigators and sponsors to inquire about trial publication status. We obtained email addresses from ClinicalTrials.gov entries, previous publications by the investigators, and online searches for contact information. A standard email was sent to each investigator with an additional email sent 2 weeks later if there was no response [11] . For trials that listed only a sponsoring company, we contacted responsible individuals by email, online forms, or telephone as per company instructions.
We reviewed identified publications in full to ensure a match with the respective Clinicaltrials.gov entry and to verify that it was a peer-reviewed article describing trial findings. We classified trials as unpublished if we could not identify a corresponding published article or if trial investigators reported that the trial was not published. A final search for trial publications was conducted on September 27, 2018, allowing a minimum of 45 months between trial completion and publication.
Statistical analyses
We used chi-squared tests and nonparametric equality of median tests to compare categorical and continuous characteristics, respectively, of completed and noncompleted trials. For completed trials, we compared characteristics of published and nonpublished trials at 2 and 4 years after trial completion. Kaplan-Meier curves were used to illustrate time to publication for completed trials, stratified by funding source. The impact of funding source on trial noncompletion was assessed with a multivariable logistic regression model with noncompletion status as the dependent variable and funding source, modeled as a set of dummy variables with industry set as the referent, as the independent variable. Effect estimates were reported as adjusted odds ratios (aORs) and 95% confidence intervals (CIs). The impact of funding source on time to publication was examined with a multivariable Cox proportional hazards model with time to publication (starting from the completion date) as the dependent variable and funding source (modeled as described above) as the independent variable. Observations were censored if not published by the end of the follow-up period (September 27, 2018). Control variables for both models were prespecified and consisted of key elements of trial design, including intervention type, trial phase, masking, and study population. Trial sample size (modeled as a piecewise linear spline with knots at the 25th, 50th, and 75th percentiles) was not included in the model examining noncompletion (since these trials halt enrollment early) but was included in the model assessing time to publication. We conducted post hoc pairwise comparisons of the five funding sources with a Bonferroni correction (with 10 pairwise comparisons, the Bonferroniadjusted alpha level for these tests was 0.05/10 = 0.005) to determine funding sources that were significantly associated with trial noncompletion and time to publication. In addition, a post hoc multivariable analysis was performed with discontinuation because of poor patient accrual (compared to trials that were completed) as the dependent variable and funding source as the independent variable (modeled as a binary variable of industry or nonindustry), using the same control variables as in the primary analyses. Statistical significance was prespecified at a P value of <0.05. All analyses were conducted in Stata/SE version 14.1 (StataCorp, College Station, TX, USA).
Results
We identified 659 randomized clinical trials studying rare diseases and meeting our inclusion criteria (Fig 1) . A total of 70,305 patients were enrolled in these trials. The most common rare disease categories studied were cancers (n = 173, 26.4%), lung diseases (n = 81, 12.3%), and nervous system diseases (n = 72, 10.9%) ( Table 1) . Industry was the primary funder for 329 trials (50.0%) and academic institutions the primary funder for 198 trials (30.0%) ( entirely in the US for 29.9% (n = 197) of trials, whereas 42.2% (n = 278) of trials were conducted entirely in other countries, and 20.0% (n = 132) were conducted in both the US and other countries (7.9% [n = 52] did not list location).
Noncompletion of trials
Of the 659 trials, 30.2% (n = 199) were discontinued. The most common reasons for trial noncompletion were insufficient patient accrual (31.2%, n = 62), informative termination (22.6%, n = 45), and company/business decision (16.0%, n = 32) ( Table 3 ). Participant enrollment was underway for 65.3% (n = 130) of trials at the time of study discontinuation, with 6,349 patients enrolled in trials that were discontinued. More than half of these patients (55.9%, n = 3,548) were enrolled in trials discontinued based on informative reasons, such as emerging safety and efficacy data related to the intervention. In univariate analysis, funding source and trial phase were significantly associated with trial noncompletion (Table 2 ). Among trials with industry funding, 24.3% (80/329) were 
Nonpublication of trials
We identified 342 publications, 114 (33.3%) in the ClinicalTrials.gov registry, 221 (64.6%) through searches in bibliographic databases, and 7 (2.1%) through correspondence with investigators and sponsors. The median follow-up since trial completion was 66 months (minimum of 45 months). Twenty-six (22%) of the unpublished trials had results posted in the ClinicalTrials.gov registry. The median time to publication was 26 months (IQR 17-37), with 66.5% (306/460) of trials unpublished at 2 years and 31.5% (142/451) at 4 years (Table 5 and Fig 2) . This corresponded to 36,581 participants in trials that were unpublished at 2 years and 11,799 participants in trials that were unpublished at 4 years. Nonpublication of trials at 2 years was associated with funding source and trial phase in univariate analyses (Table 5 ). Among completed trials funded by industry, 74.3% (185/249) were unpublished at 2 years, compared with 58.8% (80/136) of trials funded by academic institutions, 31.2% (5/16) of government-funded trials, and 57.1% (24/42) of trials funded by healthcare centers. In multivariable Cox proportional hazards models, government-funded trials were published faster than industry-funded trials (hazard ratio [HR] 1.92; 95% CI 1.06-3.49, P = 0.032), though this did not remain significant in pairwise testing of funding sources after Bonferroni correction.
Pediatric rare disease trials
Of the 79 pediatric trials for rare diseases, lung diseases (21.5%, n = 17) and nervous system diseases (13.9%, n = 11) were the most commonly studied disease categories. The median Eight trials listed a secondary reason for discontinuation, including patient accrual (n = 3), funding issue (n = 2), company/business decision (n = 1), informative termination (n = 1), and conduct problem (n = 1). 
Discussion
In this analysis of rare disease trials, over half the trials were not completed or were left unpublished 4 years after trial completion. These findings highlight considerable inefficiencies in research activities for rare diseases. Difficulties with participant accrual accounted for about a third of trial noncompletions, whereas 22% occurred for informative reasons, such as results from interim analyses. Among completed trials, almost a third were not published in the peerreviewed literature after 4 years, and there were also substantial delays among trials that were published, with greater than two-thirds unpublished at 2 years after trial completion. Funding source was a determinant of trial completion, with trials funded by industry less likely to be discontinued than trials funded by healthcare centers. In all, more than 18,000 participants were enrolled in trials that were not completed or remained unpublished 4 years after completion. Insufficient patient accrual was the most common reason for trial noncompletion. This finding is in line with prior studies assessing discontinuation across trials for various nonrare conditions and patient populations [10, 11, 17, 18] . Although analyses have demonstrated conflicting findings on the role of funding source on trial discontinuation, our results were consistent with prior studies indicating that industry-funded trials are less likely to be discontinued and also less likely to be discontinued specifically because of poor patient accrual [10, [19] [20] [21] . This may be related to greater resources and infrastructure among industry sponsors for supporting participant recruitment and retention. Informative termination was also a common reason for trial noncompletion, consistent with prior reports [10, 11, 18] . Discontinuation of certain trials related to findings in interim analysis is to be expected, and data and safety monitoring boards are specifically charged with making recommendations on the continuation or termination of a trial based on scheduled reviews. In these cases, publication of trial results to the point of discontinuation remains critical to inform future research programs and clinical care.
Nearly one in three trials for rare diseases were completed, but the results were not available in the peer-reviewed literature 4 years after trial completion. This rate of nonpublication aligns with previous studies evaluating nonpublication rates across a number of other cohorts, including surgical trials, vaccine trials, trials of neurodegenerative diseases, pediatric trials, and trials with specific types of funding sources [11, 18, [21] [22] [23] [24] . Trial nonpublication rates among these studies ranged from 25% to 35%, with median follow-up periods of 2 to 5 years. Studies examining factors associated with nonpublication have identified industry funding, early trial phase, and certain design features (e.g., single-blind status) as significant predictors of nonpublication [10] [11] [12] 21, 23] .
Children may be particularly vulnerable to the challenges of conducting clinical trials for rare diseases. However, we found similar rates of noncompletion and nonpublication among pediatric and adult studies. The pediatric trial discontinuation rate of 30% in our study is comparable with prior studies demonstrating noncompletion among 18% to 40% of trials in pediatric populations [10, 20, 25, 26] . The nonpublication rate of 24% for rare disease trials was slightly lower than previously reported rates of 30% to 37% among various cohorts of pediatric trials and may reflect improvements in this practice over time [10, 20, 25, 26] . 
Implications for clinicians and policymakers
It is estimated that 94% of rare diseases continue to lack an approved therapy [6] . Because of the scarcity of treatment options and low quality of evidence for many rare disease therapies, 35 countries have implemented regulations and policies to increase trial activity for rare diseases [4] . In 2011, the International Rare Diseases Research Consortium (IRDiRC) was launched and set a goal to be able to diagnose most rare diseases and to develop 200 new therapies by 2020 [6] . The goal for drug development was achieved in 2017, 3 years ahead of schedule, in large part because of a surge in public-sector research initiatives aimed at addressing rare diseases, improved public awareness about rare diseases, and increased engagement in partnerships between the scientific community, industry, patients, and policymakers. Building on this momentum, for the coming decade, the IRDiRC has called for a globally coordinated diagnostic and research initiative to shorten times to diagnosis and to further accelerate the rate of drug development, especially for rare diseases without existing therapeutic options [6] .
The high rate of trial discontinuation related to inadequate patient enrollment underscores the importance of establishing global initiatives and networks to coordinate recruitment efforts. In designing research programs, given the added challenges of accruing participants when patient populations are limited and geographically dispersed, proactive collaboration with rare disease experts and patient advocacy groups should be prioritized to facilitate robust enrollment forecasting and maximize trial communication to potential participants. It is also critical that stakeholders adopt a disease-focused approach to ensure patient participation in the most promising trials, as opposed to diffuse enrollment based on sponsor needs. These efforts should be designed with an eye to preventing trial initiation-and futile patient enrollment-until there is reasonable certainty that the required sample size can be achieved. Scientific review boards might play a role in this process by ensuring that only studies that are deemed feasible based on robust enrollment estimates are allowed to begin patient recruitment.
Timely publication of trial results, particularly for diseases with a scarcity of treatment options, is imperative. Beyond the scientific mandate for knowledge dissemination, trial investigators and sponsors have an ethical obligation to study participants to maximize the benefit derived from their participation in research studies [27] . Policies and initiatives such as the Declaration of Helsinki, the US Federal Policy for the Protection of Human Subjects, and the Restoring Invisible and Abandoned Trials initiative, emphasize investigators' duty to ensure timely publication of accurate and complete trial results [28] [29] [30] . ClinicalTrials.gov has supported the public posting of trial results since 2008 [31] , but investigators must also publish their results in peer-reviewed journals. The peer-review process ensures rigorous and accurate analyses, reduces study biases, and contextualizes study findings [32, 33] . Moreover, peerreviewed publications provide more accessible study results than do registries for clinicians and the scientific community, thus further supporting the dissemination and application of clinical evidence. To increase timely availability of research data, investigators can complement the peer-review process with preprint services such as medRxiv, which aim to increase the accessibility and dissemination of scientific findings [34] .
Completion and reporting of pediatric trials for rare diseases is particularly pressing [35] . Despite a number of economic incentives to increase pediatric drug research and development of therapies for pediatric rare diseases [36, 37] , a recent review reported that only 35% of 133 approved medicinal products for rare diseases were approved for use in children in the US and 47% in the European Union [38] . Policies have been implemented in the US and the EU to promote pediatric research and drug development [39] . These policies have led to increases in the number of pediatric drug trials and the number of drug labels that include pediatric prescribing information [40, 41] . However, many drugs are exempted from pediatric study requirements, whereas others are associated with pediatric trials that are delayed until many years after a drug has gained market approval for use in adults [35, 42] . In the US, the Rare Pediatric Disease Priority Review Voucher Program was implemented in 2012 to incentivize specifically the development of novel therapies for pediatric rare diseases. Given the recent initiation of the program, it remains unclear what the long-term impact of this program will be. However, a recent analysis indicates that the program has successfully increased the rate of product progression from Phase I to Phase II clinical trials but has not increased the rate of new pediatric drug development overall [37] .
Strengths and limitations
Because of a number of policies mandating trial preregistration, ClinicalTrials.gov has become the largest single trial registry and provides the most comprehensive data on trials for rare diseases worldwide [43] [44] [45] . Nonetheless, it is possible that certain interventional trials for rare diseases were conducted during the study period and not registered in the registry, in particular Phase 0 and Phase I trials, which are not required to be registered, or trials conducted entirely in non-US countries. However, our results indicate that a large number of trials conducted outside of the US are registered in ClinicalTrials.gov, which is consistent with prior reports [46] . Furthermore, it is possible that we were unable to identify all published articles resulting from completed trials. To minimize this, we employed a rigorous search strategy consisting of a standardized protocol, publication searches conducted independently by two investigators, and direct queries to investigators and sponsors, making the possibility of missed publications unlikely. In addition, we allowed for a long follow-up period-a minimum of 45 months between trial completion and publication-to ensure studies that were slow to be published would be captured. This approach also presents a limitation, however, because practices for trials registered since 2012 may have evolved, and ongoing assessments of the conduct and result dissemination of rare disease trials are needed. We also did not evaluate rates of publication of noncompleted trials, and additional research is required to further assess the dissemination of results from such trials. In particular, the publication of trials terminated for informative reasons should be assessed in order to ensure results from these trials are made available up through the point of discontinuation. Finally, we relied on trial information provided by investigators in the registry, including the status of trials, and were not able to independently verify these data elements.
Conclusions
More than half of randomized controlled trials studying rare diseases were either discontinued or remained unpublished 4 years after trial completion, resulting in large numbers of patients with rare diseases exposed to interventions that did not lead to informative findings. High rates of insufficient patient accrual highlight the importance of establishing global initiatives and networks to coordinate patient enrollment efforts in rare disease trials. Concerted efforts are needed to ensure that participation of all patients in rare disease trials advances scientific knowledge and treatments for rare diseases. 
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